The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Treatment of multiple sclerosis with an anti–interleukin‐2 receptor monoclonal antibody
Abstract
We examined whether treatment with daclizumab, a humanized monoclonal antibody specific for the interleukin‐2 receptor α chain, was safe and efficacious in relapsing–remitting and secondary progressive multiple sclerosis patients. Nineteen ambulatory patients with clinically active disease were treated for 5 to 25 months. Seventeen patients were not responding to other immunotherapies. Daclizumab was generally well tolerated. Sustained clinical improvement (10 patients) or stabilization (9 patients) was observed. Daclizumab treatment produced significant reduction in magnetic resonance imaging activity. Ann Neurol 2004
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Advances in interleukin 2 receptor targeted treatment
Morris, J. C., & Waldmann, T. A. (2000) · Annals of the Rheumatic Diseases · doi:10.1136/ard.59.suppl_1.i109 · Cited by 131
Cited by
Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa073493 · Cited by 1,746
Steinman, L., & Zamvil, S. S. (2006) · Annals of Neurology · doi:10.1002/ana.20913 · Cited by 479
Organ-specific features of natural killer cells
Shi, F.-D., Ljunggren, H.-G., La Cava, A., & Van Kaer, L. (2011) · Nature Reviews Immunology · doi:10.1038/nri3065 · Cited by 414
Wynn, D., Kaufman, M., Montalban, X., Vollmer, T., Simon, J., Elkins, J., O'Neill, G., Neyer, L., Sheridan, J., Wang, C., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70033-8 · Cited by 301
Self-citationGold, R., Giovannoni, G., Selmaj, K., Havrdova, E., Montalban, X., Radue, E.-W., Stefoski, D., Robinson, R., Riester, K., Rana, J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62190-4 · Cited by 287
Metadata
- Authors
- Rose, J. W., Watt, H. E., White, A. T., & Carlson, N. G.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2004-10-20
- Volume
- 56
- Issue
- 6
- Pages
- 864-867
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2121931605
- Cited by
- 163
- References
- 1
- FWCI
- 8.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of multiple sclerosis with an anti–interleukin‐2 receptor monoclonal antibody. https://app.cochat.ai/papers/10.1002/ana.20287
- The paper
- Rose, J. W., Watt, H. E., White, A. T., & Carlson, N. G. (2004). Treatment of multiple sclerosis with an anti–interleukin‐2 receptor monoclonal antibody. Annals of Neurology. https://doi.org/10.1002/ana.20287
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.